Jazz Pharmaceuticals (JAZZ) Tops Q2 EPS by 26c
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $225.92 +0.56%
EPS Growth %: +174.9%
Financial Fact:
Intangible asset amortization: 26.45M
Today's EPS Names:
JFIN, KEQU, LASE, More
EPS Growth %: +174.9%
Financial Fact:
Intangible asset amortization: 26.45M
Today's EPS Names:
JFIN, KEQU, LASE, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q2 EPS of $3.49, $0.26 better than the analyst estimate of $3.23. Revenue for the quarter came in at $500.48 million versus the consensus estimate of $469.62 million.
GUIDANCE:
Jazz Pharmaceuticals sees FY2018 EPS of $12.75-$13.25, versus the consensus of $13.09. Jazz Pharmaceuticals sees FY2018 revenue of $1.88-1.93 million, versus the consensus of $1.9 million.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Barclays Starts DKSH Holding AG (DKSH:SW) at Overweight
- Robinhood prices $2B convertible notes offering due 2029
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
